News & Features

CO2 Solution Obtains Exclusive Global Rights to Leading Enzyme Delivery Technology

25 Jan 2016

Agreement with CLEA Technologies B.V. provides CO2 Solution with advanced technology for industrial application of enzyme for carbon capture

QUEBEC CITY, June 1 /PRNewswire-FirstCall/ – CO2 Solution Inc. (“CO2 Solution” or the “Company”) is pleased to announce it has executed a Custom Immobilization Agreement (the “Agreement”) with CLEA Technologies B.V. (“CLEATECH”) (www.cleatechnologies.com) for the development of CLEATECH’s proprietary Cross Linked Enzyme Aggregate (“CLEA”) technology for the carbonic anhydrase enzyme used by CO2 Solution for carbon capture applications. As part of the Agreement, CO2 Solution obtains exclusive global rights to CLEATECH’s CLEA technology for the enzyme carbonic anhydrase until 2016, extendable thereafter upon commercial deployment. The CLEA technology is patent pending in the U.S. and Europe. Additionally, any new intellectual property developed under the Agreement by CLEATECH will be the sole property of CO2 Solution.

It is expected that the CLEA technology will provide for a robust method of using the carbonic anhydrase in CO2 Solution’s carbon capture process, and builds upon the proven commercial application of the CLEA technology for the fine chemicals and pharmaceutical industry. The CLEA technology provides an alternative to using soluble enzyme and may further improve overall economics of the process. Furthermore, the CLEA manufacturing process is proven, and relatively simple, allowing for expected ease of scale-up.